Several pharmaceutical companies, including AbbVie, Amgen, and Eli Lilly, have urged the U.S. Food and Drug Administration (FDA) to revise its post-approval change requirements. The drugmakers identified these regulations as significant obstacles to relocating pharmaceutical manufacturing operations back to the United States. They emphasized that current rules governing changes after a drug’s approval are too rigid and hinder efforts to modernize or adapt production processes domestically.
The companies presented their concerns during discussions with the FDA, highlighting how inflexible regulatory frameworks complicate efforts to implement necessary updates in manufacturing practices while maintaining compliance. Industry representatives argued that such barriers discourage investment in domestic facilities and impede innovation in production methods. The call for updated guidelines reflects broader industry efforts to address challenges associated with reshoring manufacturing amid global supply chain disruptions and increasing demand for localized production capabilities.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: January 13, 2026
發佈留言